Gema Biotech S.A.   Report issue

For profit Phase 3
Founded: Buenos Aires Argentina (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2015
NCT02454556
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Gema Biotech S.A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Breast Neoplasms (Phase 3)

Infertility (Phase 3)

Neutropenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4